Retatrutide Delivered with Precision

Round 2 Now Open: 85% Sold

Our Soreva Retatrutide Pen Kits are currently sold out, but production is already underway for the next batch.

We are guaranteeing shipment before December 31, 2025 for all pre-orders placed in this round.

How to Reserve Yours

To make sure you don’t miss out and to lock in special pricing, you have two options:

Reserve with a $49 Deposit

  • Pay just $49 upfront to secure your Soreva pen in the next shipment
  • This locks in the introductory price of $199
  • Your remaining balance will be due before your order ships
  • After this pre-order batch, the price will return to the regular price of $249

Why Pre-Order Now?

  • ✅ Guaranteed shipment before December 31, 2025
  • ✅ Lock in introductory pricing before it returns to $249
1 1

Soreva Retatrutide 30mg Pen Kit

Experience next-generation peptide delivery with the Soreva Retatrutide Pen Kit—a sleek, organized way to handle your Retatrutide solution. Designed around simplicity, precision, and portability, this kit keeps everything you need in one clean, modern case so you’re always prepared when it’s time to inject.

Pre-Order Soreva Retatrutide Pen Kit Now!

Our January allotment is already 85% sold. Secure your spot now.

Batch Capacity 85%
85%
View full details

“What Is Retatrutide?”

Tests & Experiments Already Done on Retatrutide

All of the tests and experiments above were conducted by Retatrutide’s original developer and research partners, not by Soreva Peptides. The results come from completed clinical studies and are still being evaluated by regulators.

Pre-Order Now

Weight-Loss Trial in People with Obesity (Phase 2 – Completed)

Who was studied: Adults with obesity or overweight with health conditions (no diabetes)

How it was done:
Randomized, double-blind, placebo-controlled study
Participants received once-weekly Retatrutide at different doses or placebo
Treatment lasted about 48 weeks

What they measured:
Change in body weight
Waist circumference and other body-composition markers
Side effects and overall safety

Main findings (published):
Average weight loss reached over 20% at the highest doses by week 48
Many participants lost at least 10–15% of their starting body weight
Most side effects were digestive (nausea, vomiting, diarrhea, constipation), mainly during dose increases

Pre-Order Now!

Type 2 Diabetes Trial (Phase 2 – Completed)

Who was studied: Adults with type 2 diabetes and excess weight.

How it was done:
Randomized, double-blind study
Once-weekly Retatrutide compared with placebo and/or standard treatments
Follow-up for several months

What they measured:
HbA1c (average blood sugar)
Body weight
Safety and side effects

Main findings (published):
HbA1c dropped by about 2 percentage points in higher-dose groups
Participants also lost a significant amount of body weight
Side-effect pattern was similar to the obesity trial (mainly digestive issues)

Pre-Order Now!

Liver Fat / Metabolic Liver Disease Sub-Studies (Completed)

Who was studied: People with obesity who also had fatty liver identified on imaging.

How it was done:
Retatrutide given once weekly, usually as part of a larger obesity trial
Liver fat measured by specialized scans at the start and after treatment

What they measured:
Percentage of fat in the liver
Liver enzyme levels (blood tests)

Main findings (published):
Retatrutide reduced liver fat substantially in many participants
Some people showed improvements in blood markers linked to liver health

Pre-Order Now!

FAQ's

  • What Is Retatrutide?

    Retatrutide (LY3437943) is an investigational peptide developed by Eli Lilly. It activates three key receptors—GLP-1, GIP, and glucagon—earning the name “triple agonist.”

  • How Retatrutide Acts in the Body

    Appetite & Fullness
    GLP-1 and GIP pathways help reduce hunger and slow stomach emptying.

    Blood-Sugar Support
    These same signals help the body release insulin more efficiently when blood sugar rises.

    Energy Use
    Glucagon-receptor activity can increase energy expenditure and help the body tap into stored fuel.

  • What have clinical trials shown so far?

    In completed phase 2 trials, people taking Retatrutide once weekly experienced substantial weight loss and improvements in metabolic markers compared to placebo. However, these are research results and do not guarantee individual outcomes or long-term safety.

Disclaimer:

For research and informational use only.
Not intended to diagnose, treat, or cure any disease.

Pre-Order Now!